GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsCHMP positive opinion is based on a robustanalytical, non-clinical and clinical data package comparing Avzivi® to thereference product Avastin® Guangzhou, China– June 3, 2024 –Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceutica...
Guangzhou, China– June 2 , 2024 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, will present aposter at the 2024 ASCO Annual Meeting entitled “Phase 1 s...
Bio-Theraand STADA have reached an exclusive commercialization and license agreement forBAT2506, a biosimilar candidate to Simponi® (golimumab) Bio-Thera will maintain responsibility fordevelopment, manufacturing, and supply of BAT2506 STADA willhav...
